Cancer Res (2022) 82 (12_Supplement): 3595. Combination treatment with RMC-6291 and SHP2 or SOS1 inhibitors was well tolerated in preclinical models and further increased anti-tumor activity, likely ...
Abstract. Lung cancer is the leading cause of cancer death worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of all lung cancers. At the time of diagnosis, it is ...
De novo pyrimidine synthesis is a universal requirement for cancer cell proliferation; however, targeting this pathway results in toxicity to all dividing cells. The rate limiting conversion of UTP to ...
Cancer Res (2023) 83 (8_Supplement): LB210.
*Corresponding Author: Sandra J. Casak, Office of Oncology Drugs, CDER, U.S. Food and Drug Administration, WO22 Room 2200, 10903 New Hampshire Avenue, Silver Spring ...
1Department of Thoracic Surgery, Cancer Hospital of Dalian University of Technology, Shenyang, China.
You do not currently have access to this content.
Cancer Discov (2026) 16 (4): OF1.
Institut de Recherches sur le Cancer, Boîte Postale n° 8 ...
Cancer Discov (2026) 16 (4): OF1.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results